Summit Therapeutics Inc. (SMMT) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 419.37M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $419.37M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $106.52M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $225.27M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $238.55M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $297.87M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $211.53M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $104.86M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $93.78M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $28.43M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $61.29M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $71.42M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $23.79M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $42.12M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $70.97M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $348.61M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $121.97M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $71.79M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $103.39M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $102.19M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $66.42M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $21.27M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $36.41M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $63.84M | (m) | (m) |
| 2019-01-31 | (m) | (m) | $35.24M | (m) | (m) |
| 2018-01-31 | (m) | (m) | $28.50M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |